Appropriate Use of Biologics in the Management of Crohn's Disease: The Role of Patient Factors in Improving Outcomes

Activity Description & Educational Objectives

In this activity, experts in inflammatory bowel diseases discuss the optimal use of biologic therapies in patients with Crohn’s disease.

Upon completion of this activity, participants should be better able to:

• Review the safety and efficacy of anti–tumor necrosis factor (TNF)α agents for the treatment of moderate-to-severe Crohn’s disease
• Apply the latest clinical findings regarding the identification, monitoring, and use of anti-TNFα therapies in patients with Crohn’s disease
• Discuss recent clinical findings related to the use of biologic therapy earlier in the treatment of moderate-to-severe Crohn's disease
• Examine barriers to the management of Crohn’s disease as they relate to patient nonadherence to medical therapy and its impact on patient outcomes
• Discuss approaches aimed at simplifying treatment regimens for patients with Crohn’s disease to ultimately improve adherence, quality of life, and outcomes

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, gastroenterology nurses, and other clinicians involved in the management of patients with Crohn’s disease.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: September 10, 2012 - September 09, 2013
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Seymour Katz, MD, FACP, MACG
Clinical Professor of Medicine
Albert Einstein College of Medicine
Bronx, New York
Attending Gastroenterologist
North Shore University Hospital–Long Island Jewish Health System
Manhasset, New York
St. Francis Hospital
Roslyn, New York

Seymour Katz, MD, FACP, MACG, has a financial interest/relationship or affiliation in the form of:

Grant/Research Support from Abbott Laboratories; Bristol-Myers Squibb; Forest Laboratories, Inc.; GlaxoSmithKline; Hutchison MediPharma Limited; Janssen Biotech, Inc. (Centocor Ortho Biotech); Millennium: The Takeda Oncology Company; Pfizer Inc.; Prometheus, Inc.; Quest; Shire; and UCB Inc.

Speakers Bureau participant with UCB Inc. and Warner Chilcott.

Interviewees

Fernando Velayos, MD, MPH
Associate Professor of Medicine
Co-Medical Director, Center for Crohn's and Colitis
University of California, San Francisco
San Francisco, California

Fernando Velayos, MD, MPH, has a financial interest/relationship or affiliation in the form of:

Honoraria from Janssen Biotech, Inc. and UCB Inc.

David T. Rubin, MD, FACG, AGAF, FACP
Professor of Medicine
Co-Director, Inflammatory Bowel Disease Center
Associate Section Chief for Educational Programs
The University of Chicago Medicine
Chicago, Illinois

David T. Rubin, MD, FACG, AGAF, FACP, has a financial interest/relationship or affiliation in the form of:

Consultant for Abbott Immunology; Bristol-Myers Squibb; Elan Pharmaceuticals, Inc.; Exagen Diagnostics, Inc.; Given Imaging Ltd.; Ironwood Pharmaceuticals, Inc.; Janssen Biotech, Inc. (Centocor Ortho Biotech); Lifecore Biomedical, LLC; Millennium: The Takeda Oncology Company; Prometheus, Inc.; Salix Pharmaceuticals, Inc.; Shire; and UCB Inc.

Grant/Research Support from Abbott Immunology (Registry); Elan Pharmaceuticals, Inc. (Registry); Procter & Gamble; Prometheus, Inc.; Salix Pharmaceuticals, Inc.; Shire; and Warner Chilcott.

Speakers Bureau participant with Merck & Co., Inc. in the form of non-US and not promotional.

Other Financial or Material Support from Cornerstones Health Inc. Dr. Rubin is a Co-Founder of the non-profit educational entity.

Medical Director

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # 5157-13-T.

This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

This activity is supported by educational grants from Abbott, Janssen Biotech, Inc administered by Janssen Services, LLC, and UCB, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.